JGP Global Gestao de Recursos Ltda. raised its holdings in Incyte Co. (NASDAQ:INCY) by 1.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,701 shares of the biopharmaceutical company’s stock after purchasing an additional 196 shares during the period. Incyte comprises approximately 0.5% of JGP Global Gestao de Recursos Ltda.’s holdings, making the stock its 19th largest holding. JGP Global Gestao de Recursos Ltda.’s holdings in Incyte were worth $1,546,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Covenant Asset Management LLC grew its position in shares of Incyte by 10.9% during the fourth quarter. Covenant Asset Management LLC now owns 18,140 shares of the biopharmaceutical company’s stock worth $1,584,000 after buying an additional 1,781 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Incyte in the fourth quarter valued at $740,000. Lucia Wealth Services LLC acquired a new stake in Incyte in the fourth quarter valued at $1,075,000. Patriot Financial Group Insurance Agency LLC bought a new position in Incyte during the 4th quarter valued at $44,000. Finally, Savior LLC acquired a new position in Incyte during the 4th quarter worth $27,000. 90.89% of the stock is currently owned by institutional investors.

Several equities research analysts have recently weighed in on the stock. Citigroup reissued an “outperform” rating and issued a $96.00 target price (down previously from $100.00) on shares of Incyte in a research report on Friday, January 3rd. Piper Jaffray Companies reiterated a “buy” rating and issued a $95.00 price target on shares of Incyte in a research note on Thursday, January 2nd. Guggenheim lowered Incyte from a “buy” rating to a “neutral” rating in a report on Thursday, January 2nd. Morgan Stanley cut their price objective on Incyte from $89.00 to $83.00 and set an “equal weight” rating on the stock in a research note on Monday, January 6th. Finally, ValuEngine raised Incyte from a “sell” rating to a “hold” rating in a report on Saturday, January 4th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $92.18.

Shares of Incyte stock traded down $1.64 on Friday, reaching $76.60. 80,702 shares of the company were exchanged, compared to its average volume of 1,559,168. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.01 and a current ratio of 5.02. The company’s 50-day moving average is $85.84 and its two-hundred day moving average is $82.75. The firm has a market cap of $16.85 billion, a price-to-earnings ratio of 41.11, a P/E/G ratio of 0.88 and a beta of 0.97. Incyte Co. has a 1-year low of $72.00 and a 1-year high of $96.79.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.27. The business had revenue of $551.58 million during the quarter, compared to analyst estimates of $534.73 million. Incyte had a return on equity of 20.07% and a net margin of 19.21%. The business’s revenue for the quarter was up 22.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.41 EPS. As a group, sell-side analysts forecast that Incyte Co. will post 2.14 earnings per share for the current year.

In other Incyte news, EVP Yao Wenqing sold 2,040 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $85.00, for a total transaction of $173,400.00. Following the completion of the transaction, the executive vice president now directly owns 47,348 shares of the company’s stock, valued at approximately $4,024,580. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wendy L. Dixon sold 10,576 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $84.16, for a total transaction of $890,076.16. Following the completion of the transaction, the director now owns 22,916 shares of the company’s stock, valued at approximately $1,928,610.56. The disclosure for this sale can be found here. Insiders sold 131,436 shares of company stock worth $11,394,110 over the last ninety days. 17.10% of the stock is owned by corporate insiders.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Further Reading: Trading Ex-Dividend

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.